Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta

Comparison With Normal Individuals and Response to Teriparatide Therapy

Lindsey Nicol, Ying Wang, Rosamund Smith, John Sloan, Sandesh C.S. Nagamani, Jay Shapiro, Brendan Lee, Eric Orwoll

Research output: Contribution to journalArticle

Abstract

Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p < 0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01). The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI.

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalJournal of Bone and Mineral Research
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Teriparatide
Osteogenesis Imperfecta
Serum
Therapeutics
Bone Density
Placebos
Bone and Bones
Osteocytes
Bone Remodeling
Bone Fractures
Collagen Type I
Area Under Curve
Glycoproteins
Randomized Controlled Trials
Biomarkers

Keywords

  • OSTEOGENESIS IMPERFECTA
  • SCLEROSTIN (SOST)
  • TERIPARATIDE

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta : Comparison With Normal Individuals and Response to Teriparatide Therapy. / Nicol, Lindsey; Wang, Ying; Smith, Rosamund; Sloan, John; Nagamani, Sandesh C.S.; Shapiro, Jay; Lee, Brendan; Orwoll, Eric.

In: Journal of Bone and Mineral Research, Vol. 33, No. 2, 01.02.2018, p. 307-315.

Research output: Contribution to journalArticle

Nicol, Lindsey ; Wang, Ying ; Smith, Rosamund ; Sloan, John ; Nagamani, Sandesh C.S. ; Shapiro, Jay ; Lee, Brendan ; Orwoll, Eric. / Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta : Comparison With Normal Individuals and Response to Teriparatide Therapy. In: Journal of Bone and Mineral Research. 2018 ; Vol. 33, No. 2. pp. 307-315.
@article{a31d1fb39d454b20b7cde38bb5deaf4b,
title = "Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy",
abstract = "Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p < 0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01). The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI.",
keywords = "OSTEOGENESIS IMPERFECTA, SCLEROSTIN (SOST), TERIPARATIDE",
author = "Lindsey Nicol and Ying Wang and Rosamund Smith and John Sloan and Nagamani, {Sandesh C.S.} and Jay Shapiro and Brendan Lee and Eric Orwoll",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/jbmr.3312",
language = "English (US)",
volume = "33",
pages = "307--315",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta

T2 - Comparison With Normal Individuals and Response to Teriparatide Therapy

AU - Nicol, Lindsey

AU - Wang, Ying

AU - Smith, Rosamund

AU - Sloan, John

AU - Nagamani, Sandesh C.S.

AU - Shapiro, Jay

AU - Lee, Brendan

AU - Orwoll, Eric

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p < 0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01). The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI.

AB - Sclerostin (SOST), a glycoprotein primarily derived from osteocytes, is an important regulator of bone remodeling. Osteogenesis imperfecta (OI) is a heritable disorder of bone characterized by low bone mass, bone fragility, recurrent fractures, and bone deformities. Altered SOST-mediated signaling may have a role in pathogenesis of type I collagen-related OI; however, this has not been evaluated in humans. We measured serum SOST levels in adults with OI who were enrolled in a randomized, placebo-controlled clinical trial that evaluated the effects of osteoanabolic therapy with teriparatide. Compared with age- and sex-matched control participants, mean SOST levels were lower in those with type I or types III/VI OI (p < 0.0001). Receiver operating curve analysis revealed that sclerostin alone or sclerostin plus bone mineral content discriminated patients with OI from controls (area under the curve 0.80 and 0.87, respectively). SOST levels increased in the group of patients with type I OI during therapy with teriparatide (compared with placebo, p = 0.01). The increase was significant at 6, 12, and 24 months of therapy (p ≤ 0.02) and was apparent as early as 3 months (p = 0.06). The magnitude of increases in SOST levels during therapy was inversely correlated with increases in vertebral volumetric bone mineral density (vBMD). Overall, these results suggest that: 1) SOST regulation is fundamentally altered in osteogenesis imperfecta; 2) serum SOST levels could be a biomarker of OI in adults; and 3) alterations in SOST may help predict the response to anabolic therapies in OI.

KW - OSTEOGENESIS IMPERFECTA

KW - SCLEROSTIN (SOST)

KW - TERIPARATIDE

UR - http://www.scopus.com/inward/record.url?scp=85041945954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041945954&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3312

DO - 10.1002/jbmr.3312

M3 - Article

VL - 33

SP - 307

EP - 315

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -